Emcure Pharmaceuticals Limited

Equities

End-of-day quote NSE India S.E. Other stock markets 16/03/2026			5-day change	1st Jan Change
1,458.40 ^INR	+1.42%		-4.12%	+6.88%

02/03	Emcure Pharmaceuticals and Roche sign distribution agreement in India	RE
02/03	Emcure Pharmaceuticals Limited and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India	CI

Published on 02/04/2026 at 10:38 pm IST - Modified on 03/06/2026 at 08:22 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, good day, and welcome to Emcure Pharmaceuticals Limited Q3 FY '26 Earnings Conference Call. [Operator Instructions] Please note

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

02/03	Emcure Pharmaceuticals and Roche sign distribution agreement in India	RE
02/03	Emcure Pharmaceuticals Limited and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India	CI
09/02	Emcure Pharma Reports Fire Incident at Pune Manufacturing Plant	MT
05/02	Jefferies Adjusts Emcure Pharmaceuticals' Price Target to INR1,780 From INR1,740, Keeps at Buy	MT
04/02	Emcure Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 04, 2026
04/02	Emcure Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
04/02	Emcure Pharmaceuticals Dec-quarter Consol Net Profit 2.31 Billion Rupees	RE
04/02	Emcure Pharmaceuticals Limited Appoints Amruta Jana Yangalwar as Company Secretary and Compliance Officer, Effective February 4, 2026	CI
31/01	Delhivery Limited Announces Board Changes	CI
29/01	Emcure Pharmaceuticals Witnesses a Growth Spurt
20/01	Sun Pharma Announces Sana Shaikh Takes Charge as Head of Marketing	CI
09/01	37,959,271 Equity Shares of Emcure Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 9-JAN-2026.	CI
24/12	India equity benchmarks set for muted start amid foreign outflows, thin trading volumes	RE
24/12	Lilly, Novo lock horns in India's obesity drug race	RE
23/12	Emcure Pharmaceuticals says Gujarat facility receives 'No Action Indicated' from US FDA	RE